RAPP

23.1801.74%
JS

Jeffrey Sevigny

Chief Medical Officer

Dr. Jeffrey Sevigny, also known as Jeff, M.D. is Chief Medical Officer of Rapport Therapeutics, Inc. from March 03, 2025. Dr. Sevigny had been an Independent Director of Acumen Pharmaceuticals, Inc. since July 2019 until August 16, 2022 and served as its Member of Clinical & Scientific Advisory Board until August 16, 2022. Dr. Sevigny has served as Chief Medical Officer of Prevail Therapeutics Inc., since joining on March 01, 2018 until February 2025. Prior to Prevail Therapeutics Inc., he served as Vice President and Global Head of Translational Medicine Neuroscience at Roche from January 2016 to March 2018. From February 2021 to January 2025, Dr. Sevigny also served as Senior Vice President of Neuroscience at Eli Lilly. Previously, Dr. Sevigny served on the boards of directors of Prevail from June 2019 to January 2021. He was Senior Director of Clinical Development at Biogen Inc., a multinational biotechnology company, from September 2010 to January 2016. Previously, he served as Principal Medical Scientific Expert of Neuroscience at Novartis AG, a multinational pharmaceutical company and as Associate Director of Neuroscience at Merck. Dr. Sevigny has also held academic appointments as Assistant Professor of Neurology at Albert Einstein School of Medicine and Assistant Professor of Clinical Neurology at Columbia University College of Physicians and Surgeons. He has experience in neurology and specifically neurodegenerative disorders. Dr. Sevigny received an M.D. from Tufts University School of Medicine and an A.B. in biochemistry from Bowdoin College. He completed a neurology residency at the Neurological Institute of New York at Columbia University Medical Center and a fellowship in Aging & Dementia and Neuro-Epidemiology at Sergievsky Center at Columbia University and Columbia University Mailman School of Public Health.

Positions